Download PDF
Semin Thromb Hemost 2002; 28(2): 161-166
DOI: 10.1055/s-2002-27818
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

A Reliable von Willebrand Factor: Ristocetin Cofactor Enzyme-Linked Immunosorbent Assay to Differentiate between Type 1 and Type 2 von Willebrand Disease

Karen Vanhoorelbeke, Nancy Cauwenberghs, Griet Vandecasteele, Stephan Vauterin, Hans Deckmyn
  • Laboratory for Thrombosis Research, IRC, KU Leuven Campus Kortrijk, Belgium
Further Information

Publication History

Publication Date:
03 May 2002 (online)

    Permissions and Reprints

ABSTRACT

von Willebrand disease (vWD) is the most common hereditary bleeding disorder due to either a qualitative or a quantitative defect in von Willebrand factor (vWF). vWF is a multimeric plasma protein that plays an important role in (1) primary hemostasis, by sustaining indirect platelet adhesion especially at high shear rates, and in (2) secondary hemostasis, by protecting factor VIIIc (FVIIIc) from degradation. A correct diagnosis of vWD is based on the accurate identification of one of the six different subtypes (type 1, 2A, 2B, 2M, 2N, 3). To do this, different laboratory tests are available. One aspect of the identification is the discrimination between type 1 and type 2 (2A, 2B, and 2M) vWD. In type 1 vWD, both vWF levels (vWF:Ag) and vWF activity (vWF:RCof) are decreased; in type 2, the vWF:Ag level is normal or decreased and vWF:RCof is decreased. Thus, ratios of vWF:Ag to vWF:RiCof above 1 allow identifation of type 2 vWD patients. The currently used vWF:RCof test is an agglutination test in which patients' plasma is added to washed fixed control platelets in the presence of ristocetin and the extent of agglutination is measured. This test suffers from high interlaboratory and intralaboratory variability. We have recently shown that the same vWF:RCof can also be measured in an enzyme-linked immunosorbent assay (ELISA) with a low interassay and intraassay variability and can be used to identify patients suffering from vWD. We here show that our test allows the discrimination between type 1 and type 2 vWD patients.

KEYWORDS

von Willebrand disease - ristocetin cofactor activity - ELISA - diagnosis - factor VIIIc

REFERENCES

  • 1 Kehrel B. Platelet-collagen interactions.  Semin Thromb Hemost . 1995;  21 123-129
    PubMedSearch in Google Scholar
  • 2 Sakariassen K S, Bolhuis P A, Sixma J J. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium.  Nature . 1979;  279 636-638
    CrossrefPubMedSearch in Google Scholar
  • 3 Savage B, Saldivar E, Ruggeri Z M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.  Cell . 1996;  84 289-297
    CrossrefPubMedSearch in Google Scholar
  • 4 Lopez J A, Andrews R K, Afshar-Kharghan V. Bernard-Soulier syndrome.  Blood . 1998;  91 4397-4418
    PubMedSearch in Google Scholar
  • 5 Mazurier C, Ribba A S, Gaucher C. Molecular genetics of von Willebrand disease.  Ann Genet . 1998;  41 34-43
    PubMedSearch in Google Scholar
  • 6 Mohlke K L, Nichols W C, Ginsburg D. The molecular basis of von Willebrand disease.  Int J Clin Lab Res . 1999;  29 1-7
    CrossrefPubMedSearch in Google Scholar
  • 7 Sadler J E. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.  Thromb Haemost . 1994;  71 520-525
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Favaloro E J, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease.  Pathology . 1997;  29 385-391
    CrossrefPubMedSearch in Google Scholar
  • 9 Federici A B. Diagnosis of von Willebrand disease.  Haemophilia . 1998;  4 654-660
    CrossrefPubMedSearch in Google Scholar
  • 10 Veyradier A, Fressinaud E, Meyer D. Laboratory diagnosis of von Willebrand disease.  Int J Clin Lab Res . 1998;  28 201-210
    CrossrefPubMedSearch in Google Scholar
  • 11 Favaloro E J, Grispo L, Exner T. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease.  Blood Coagul Fibrinolysis . 1991;  2 285-291
    CrossrefPubMedSearch in Google Scholar
  • 12 Favaloro E J, Smith J, Petinos P. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel.  Thromb Haemost . 1999;  82 1276-1282
    PubMedSearch in Google Scholar
  • 13 Vanhoorelbeke K, Cauwenberghs N, Vauterin S. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor.  Thromb Haemost . 2000;  83 107-113
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Schumpp-Vonach B, Kresbach G, Schlaeger E J. Stable expression in Chinese hamster ovary cells of a homogeneous recombinant active fragment of human platelet glycoprotein Ib alpha.  Cytotechnology . 1995;  17 133-141
    CrossrefPubMedSearch in Google Scholar
  • 15 Macfarlane D E, Stibbe J, Kirby E P. A method for assaying von Willebrand factor (ristocetin cofactor).  Thrombosis et Diathesis Haemorrhagica (Letter) . 1975;  34 306-308
    PubMedSearch in Google Scholar
  • 16 Brinkhous K M, Graham J E, Cooper H A. Assay of von Willebrand factor in von Willebrand's disease and hemophilia: use of a macroscopic platelet aggregation test.  Thromb Res . 1975;  6 267-272
    CrossrefPubMedSearch in Google Scholar
  • 17 Federici A B, Bader R, Pagani S. Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size.  Br J Haematol . 1989;  73 93-99
    PubMedSearch in Google Scholar
  • 18 Fischer B E, Kramer G, Mitterer A. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.  Thromb Res . 1996;  84 55-66
    CrossrefPubMedSearch in Google Scholar
  • 19 de Romeuf C, Hilbert L, Mazurier C. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.  Thromb Haemost . 1998;  79 211-216
    PubMedSearch in Google Scholar
  • 20 Vanhoorelbeke K, van der Plas M R, Vandecasteele G. Sequence alignment between vWF and peptides inhibiting the vWF-collagen interaction does not result in the identification of a collagen-binding site in vWF.  Thromb Haemost . 2000;  84 621-625
    PubMedSearch in Google Scholar
  • 21 Brown J E, Bosak J O. An ELISA test for the binding of von Willebrand antigen to collagen.  Thromb Res . 1986;  43 303-311
    CrossrefPubMedSearch in Google Scholar
  • 22 Favaloro E J, Henniker A, Facey D. Discrimination of von Willebrand's disease (vWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (vWF:CBA) with monoclonal antibody (MAB) based vWF-capture systems.  Thromb Haemost . 2000;  84 541-547
    PubMedSearch in Google Scholar
  • 23 Favaloro E J. Collagen binding assay for von Willebrand factor (vWF:CBA): detection of von Willebrands disease (vWD), and discrimination of vWD subtypes, depends on collagen source.  Thromb Haemost . 2000;  83 127-135
    PubMedSearch in Google Scholar
  • 24 Murdock P J, Woodhams B J, Matthews K B. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use.  Thromb Haemost . 1997;  78 1272-1277
    Thieme ConnectPubMedSearch in Google Scholar
  • 25 Preston F E. Assays for von Willebrand factor functional activity: a UK NEQAS survey. National External Quality Assessment Scheme. (Letter) (published erratum appears in Thromb Haemost 1999;81:478) .  Thromb Haemost . 1998;  80 863
    PubMedSearch in Google Scholar
  • 26 Hillery C A, Mancuso D J, Evan S J. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.  Blood . 1998;  91 1572-1581
    PubMedSearch in Google Scholar